НовостиBenzingaSatellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age Benzinga 2026.09.30 11:13 (GMT+0) Открыть на Benzinga Другие новости